A recent study suggested that cancer-cell-derived IL-33 is necessary to synergize with Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4) or Programmed Cell Death 1 (PD-1) monoclonal antibodies (mAbs) to enhance antitumor efficacy [72]. The gene discussed is PDCD1; the disease is cancer.